APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of March 2, 2026, APRE stock price declined to $0.89 with 113,565 million shares trading.

APRE has a beta of 2.23, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.30 to the broad based SPY ETF.

APRE has a market cap of $6.19 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APRE traded as high as $8.85 and as low as $.55.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VXF.

APRE has underperformed the market in the last year with a return of -64.6%, while the SPY ETF gained +18.6%. In the last 3 month period, APRE fell short of the market, returning -29.2%, while SPY returned +1.3%. However, in the most recent 2 weeks APRE has outperformed the stock market by returning +45.2%, while SPY returned +0.7%.

APRE support price is $.83 and resistance is $1.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE shares will trade within this expected range on the day.